Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
ACE Report #10021
Ace Report Cover Spine

E. coli-derived rhBMP-2 offers similar fusion success to AIBG in posterolateral lumbar fusion

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial

Spine J. 2017 Dec;17(12):1866-1874

Contributing Authors: JH Lee HJ Kim KH Koo CK Lee KB Lee H Kim KS Suk JJ Yang JH Cho CJ Hwang J Han JS Yeom BS Chang WD Nam

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


100 patients scheduled for posterolateral fusion due to severe spinal stenosis, grade 1 spondylolisthesis, or spondylolysis were randomized to graft material of either Escherichia coli-derived recombinant human bone morphogenetic protein-2 (rhBMP-2) in a hydroxyapatite carrier or an autologous iliac crest bone graft. Patients were assessed primarily for fusion success on CT at 12 and 24 weeks. Sec...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.